Co-Diagnostics announced that its Logix Smart ABC Test (Influenza A/Influenza B/COVID-19) is anticipated to be ready for launch to U.S. CLIA laboratories the first week of October 2020, according to a press release.
“Co-Diagnostics is committed to participating in the fight against COVID-19 through the development and manufacture of vital diagnostic testing solutions, with none perhaps as important as this upcoming ABC multiplex test,” remarked Dwight Egan, CEO of Co-Diagnostics. “Our patented CoPrimer technology platform is ideally suited for multiplex reactions by substantially reducing ‘primer-dimers,’ a phenomenon in PCR molecular tests that results in false positive results. At a time when the need for accurate detection of COVID-19, as well as the differentiation between strains of the flu, has never been greater, we are pleased to be able to contribute to the safety and well-being of communities across the country and around the world.”
The test will be made available initially to CLIA labs to use with their own laboratory developed tests (LDTs), while the company proceeds with the FDA Emergency Use Authorization (EUA) submission and CE marking registration.
